There is a significant unmet need for additional treatment options for high-grade NMIBC, especially in those ineligible for BCG.
TipRanks on MSN
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors
Relmada Therapeutics Inc ($RLMD) announced an update on their ongoing clinical study. Relmada Therapeutics is preparing to launch a late-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback